ANDA 210140, held by Zydus Lifesciences. Doxepin Hydrochloride.
As of Nov 16, 2026, ANDA 210140 (Doxepin Hydrochloride), held by Zydus Lifesciences, was first approved by FDA on Mar 21, 2023, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 21, 2023 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Doxepin HydrochlorideEQ 150MG BASE ยท capsule;oral | Doxepin Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters